Greenwich LifeSciences, Inc. (GLSI) Stock

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is led by CEO Snehal S. Patel, employs 4 people, headquartered in US, publicly traded since 2020.

Greenwich LifeSciences, Inc. (GLSI) stock trades at $16.03 with a market capitalization of $235.29M. The stock is valued at a negative price-to-earnings (P/E) ratio of -11.03, reflecting a net loss over the last twelve months, price-to-book of 79.65, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.78 and $34.10, and currently trades 53.0% below its 52-week high.

On profitability, Greenwich LifeSciences, Inc. generates a return on equity (ROE) of -793.76% (negative, reflecting a net loss), return on capital employed of -701.55%.

Greenwich LifeSciences, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Greenwich LifeSciences, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-19.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-22.0M.

Borrowings stand at $0, cash from operations was $-10.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -383.1% over five years, and was -1700.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Greenwich LifeSciences, Inc. (GLSI) — frequently asked questions